Prosecution Insights
Last updated: November 20, 2026
Application No. 18/704,810

AGENT FOR INHIBITING PROLIFERATION OF SARS-CoV-2

Non-Final OA §102§112
Filed
Apr 25, 2024
Priority
Oct 29, 2021 — JP 2021-177339 +1 more
Examiner
KARUNASENA, ENUSHA
Art Unit
1653
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kirin Holdings Kabushiki Kaisha
OA Round
1 (Non-Final)
33%
Grant Probability
At Risk
1-2
OA Rounds
2m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants only 33% of cases
33%
Career Allowance Rate
2 granted / 6 resolved
-26.7% vs TC avg
Strong +100% interview lift
Without
With
+100.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
27 currently pending
Career history
44
Total Applications
across all art units

Statute-Specific Performance

§101
9.0%
-31.0% vs TC avg
§103
30.3%
-9.7% vs TC avg
§102
24.1%
-15.9% vs TC avg
§112
26.9%
-13.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 6 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 11-17 are pending and under examination. Claims 1-10 are cancelled. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 11-17 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for treating COVID-19 comprised of administering a lactic acid bacterium of claim11, does not reasonably provide enablement for preventing COVID-19 comprised of lactic acid bacterium of claim 11. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. Enablement is considered in view of the Wands factors (MPEP 2164.01 (a)). The court in Wands states: "Enablement is not precluded by the necessity for some experimentation such as routine screening. However, experimentation needed to practice the invention must not be undue or reasonable experimentation. (Wands, 8 USPQ2d 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. "Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations." (Wands, 8 USPQ2d 1404). The factors to be considered in determining whether undue experimentation is required include: (A) The nature of the invention; (B) The breadth of the claims; (C) The amount of direction provided by the inventor; (D) The existence of working examples; (E) The state of the prior art; (F) The level of predictability in the art; (G) The quantity of experimentation needed to make or use the invention based on the content of the disclosure and (H) The level of one of ordinary skill. While all of these factors are considered, a sufficient amount for a prima facie case are discussed below. The nature of the invention and breadth of the claims: The claims are broadly drawn to a method for preventing or treating COVID-19 comprising administration of a lactic acid bacterium, including Lactococcus lactis subsp. Lactis JCM 5805. The instant specification does not define the term prevent. The Merriam-Webster defined prevent as to keep from happening or existing. Thus, the instant claims includes a method comprised of administering a lactic acid bacterium, including Lactococcus lactis subsp. Lactis JCM 5805, that will completely hinder even one COVID-19 viral particle from infecting a subject. The state of the art/the level of predictability in the art: Based on the state of the art and the instant specification, administration of ANY lactic acid bacterium, including Lactococcus lactis subsp. Lactis JCM 5805, has not been shown to prevent the occurrence of COVID-19. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention to prevent COVID-19. The quantity of experimentation needed to make or use the invention based on the content of the disclosure: Studies and/or therapeutics for the treatment of COVID-19 and/or prevention are active to improve disease symptoms. As disclosed by the prior art, and instant application, there are clinically relevant outcomes, post-diagnosis with COVID-19, wherein patients benefited from lactic acid bacteria to minimize the longevity of symptoms, along with reduced use of antibiotics, and/or experimental data which demonstrate modified and beneficial immune response. However, based on the instant disclosure and prior art, there is a lack of scientific data, such that the evidence does not provide sufficient support demonstrating administration of the claimed lactic acid bacterium (or any other lactic acid bacteria) prevents the onset of COVID-19. As noted, instant application and state of the art provide therapeutic effects associated with administration of Lactococcus lactis subsp. Lactis JCM 5805 or other lactic acid bacteria, post- viral infection and/or following the development of symptoms. However, these observations do not establish prevention, with the administration of the claimed bacterium prior to infection. The specification does not provide experimental data supporting a preventive effect, such as a reduction in COVID-19 onset, prior to infection with the administration of the claimed lactic acid bacterium. Additionally, instant application and the state-of-the art, does not provide sufficient scientific data from which one of ordinary skill in the art would have been able to reliably predict a preventative outcome, from prophylactic treatment , by administration of Lactococcus lactis subsp. Lactis JCM 5805 or other lactic acid bacteria. Therefore, in order to practice the invention as claimed, one of ordinary skill in the art would have to perform undue experimentation to develop a method which accurately predicts COVID-19 prevention. Conclusion: Applicant is enabled for treatment of COVID-19 comprised of administering a lactic acid bacterium of claim 11. However, in view of the Wands factors as discussed above, one of ordinary skill in the art would have to engage in undue experimentation to practice the full scope of the instant claimed invention. The dependent claims are rejected since they do not resolve the enablement issues. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 11-17 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Pourhossein,M. et al., Probiotics in viral infections, with a focus on COVID:19: A Systematic Review. Authorea Pre-print. (https://doi.org/10.22541/au.158999387.76467979). May 20,2020. pp. 1-10 and evidenced by U.S. NCBI Taxonomy Browser (Lactococcus lactis subsp. lactis JCM 5805 = NBRC 100933). Regarding claim 11, Pourhossein et al., discloses the efficacy of single probiotics for the treatment of viral-based infectious diseases and the cumulative review of more than 20 strains which improved the anti-inflammatory interleukins and antibody production against viruses (page 5, Conclusion’)—including viral complications resulting from SARS-CoV-2 infection and the disease conditions of COVID-19; wherein a step for administering a composition comprising the lactic acid bacterium to a subject in need thereof, includes as disclosed by Pourhossein et al : several different lactic acid producing bacteria along with minerals and vitamins given to a COVID-19 case, the nutritional support lowered complications of massive antibiotic therapy (page 2; ‘Introduction’, paragraph 2). Regarding claim 12, 13, and 14, Pourhossein et al., discloses multiple antiviral impacts of probiotics in the context of COVID-19 symptoms and targeted molecular/cellular pathways, including Lactococcus lactis JCM5805 (Lactococcus lactis subspecies lactis as evidenced by, U.S. database NCBI Taxonomy ID 1236944) which can activate human plasmacytoid dendritic cells (pDCs) and play a crucial role in antiviral immunity as proficient type I IFN producing cells (IPCs) (page 5; ‘Discussion’, paragraph 1). Regarding claims 15 and 16 Pourhossein et al., discloses oral administration of a yogurt containing a lactic acid bacterium, Lactobacillus gasseri SBT2055, to potentiate antibody titers against viruses (page 4, ‘3.1.3 Effects on Antibody Production’, paragraph 2). Regarding claim 17, Pourhossein et al., discloses a lactic acid bacterium administered in a capsule (pharmaceutical composition) that increases CD3+CD69+ cells and interferon-gamma levels (page 3; 3.1.3 Effects on antibody production’, paragraph 1). Conclusion No claims are currently deemed patentable. Correspondence Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to ENUSHA KARUNASENA whose telephone number is (571)272-3972. The examiner can normally be reached Monday-Friday 7:30am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ENUSHA KARUNASENA/Examiner, Art Unit 1653 /JULIE WU/Supervisory Patent Examiner, Art Unit 1643
Read full office action

Prosecution Timeline

Apr 25, 2024
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §102, §112 (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
33%
Grant Probability
99%
With Interview (+100.0%)
2y 9m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 6 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month